单位：[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China肿瘤科华中科技大学同济医学院附属同济医院[2]School of Pharmacy, Hubei University of Science and Technology, Xianning, China[3]Division of Gastrointestinal Surgery, Department of General Surgery, Huai'an Second People's Hospital, the Affiliated Huai'an Hospital of Xuzhou Medical University, Huaian, China
The application of immune checkpoint inhibitor (ICI) using monoclonal antibodies has brought about a profound transformation in the clinical outcomes for patients grappling with advanced gastric cancer (GC). Nonetheless, despite these achievements, the quest for effective functional biomarkers for ICI therapy remains constrained. Recent research endeavours have shed light on the critical involvement of modified epigenetic regulators in the pathogenesis of gastric tumorigenesis, thus providing a glimpse into potential biomarkers. Among these regulatory factors, AT-rich interaction domain 1A (ARID1A), a pivotal constituent of the switch/sucrose non-fermentable (SWI/SNF) complex, has emerged as a promising candidate. Investigations have unveiled the pivotal role of ARID1A in bridging the gap between genome instability and the reconfiguration of the tumour immune microenvironment, culminating in an enhanced response to ICI within the landscape of gastric cancer treatment. This all-encompassing review aims to dissect the potential of ARID1A as a valuable biomarker for immunotherapeutic approaches in gastric cancer, drawing from insights garnered from both preclinical experimentation and clinical observations.
基金：
Chinese Society of Clinical Oncology
(CSCO)-Hengrui Cancer Research
Fund, Grant/Award Number:
Y-HR2020QN-0946; the Key Project
of the Education Commission of Hubei
Province, Grant/Award Number:
D20202802; the National Natural Science
Foundation of China, Grant/Award
Number: 81974483 and 82072589
第一作者单位：[1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
共同第一作者：
通讯机构：[*1]Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.[*2]Division of Gastrointestinal Surgery, Department of General Surgery, Huai'an Second People's Hospital, the Affiliated Huai'an Hospital of Xuzhou Medical University, Huaian, Jiangsu Province, China.
推荐引用方式(GB/T 7714)：
Zhang Xuemei,Zhang Youzhi,Zhang Qiaoyun,et al.Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives[J].JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.2024,28(5):doi:10.1111/jcmm.18063.
APA：
Zhang, Xuemei,Zhang, Youzhi,Zhang, Qiaoyun,Lu, Mengyao,Chen, Yuan...&Zhang, Peng.(2024).Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives.JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,28,(5)
MLA：
Zhang, Xuemei,et al."Role of AT-rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives".JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 28..5(2024)
医学